Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders

Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2024-05, Vol.30 (3), p.648-657
Main Authors: Al-Huniti, Ahmad, Marshall, Linda, Rusk, Dawn, Pruthi, Rajiv K, Rodriguez, Vilmarie, Ferdjallah, Asmaa, Kuhn, Alexis
Format: Article
Language:English
Subjects:
Antifibrinolytic agents
Antifibrinolytic Agents - administration & dosage
Antifibrinolytic Agents - therapeutic use
Bleeding
Blood Coagulation Disorders - drug therapy
Child
Child, Preschool
Children
Female
Hemophilia
Hemorrhage - drug therapy
Humans
Infant
Male
Patients
Pediatrics
Retrospective Studies
Tablets
Tranexamic Acid - administration & dosage
Tranexamic Acid - therapeutic use
Water
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c273t-33269456ac1a3c956dec2523bfd3482811b872533a84fa576ae86f995f2150313
container_end_page 657
container_issue 3
container_start_page 648
container_title Haemophilia : the official journal of the World Federation of Hemophilia
container_volume 30
creator Al-Huniti, Ahmad
Marshall, Linda
Rusk, Dawn
Pruthi, Rajiv K
Rodriguez, Vilmarie
Ferdjallah, Asmaa
Kuhn, Alexis
description Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders. We retrospectively reviewed records of children ( .1). No patients had adverse effects. Eight of 19 patients (42%) who were initially prescribed EACA OS did not receive it because of cost or insurance denial. The estimated average wholesale price of one treatment was $94 for cTXAw and $905 for EACA OS. CTXAw appears to be an effective, safe, and low-cost alternative option to EACA OS for young children with bleeding disorders.
doi_str_mv 10.1111/hae.14996
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2973100966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2973100966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c273t-33269456ac1a3c956dec2523bfd3482811b872533a84fa576ae86f995f2150313</originalsourceid><addsrcrecordid>eNpdkD1PwzAQhi0EoqUw8AeQJRYYUmxf7MQjqviSKrHQ2XIch7rKF3aiwr_HpYWBW-4sP3p19yB0ScmcxrpbazunqZTiCE0pCJ4wTsXxbuY0yRkVE3QWwoYQCoyIUzSBnJOMgZwitQoWdxU2fgxrW-LB69Z-6sYZrI2Lb13UdgjYtXirB-tx1Xnca1s6PfgI9Xpwto3A1g1rHNn4077j0oXOl9aHc3RS6TrYi0OfodXjw9viOVm-Pr0s7peJYRkMCQATMuVCG6rBSC5KaxhnUFQlpDnLKS3yjHEAnaeV5pnQNheVlLxilBOgMEM3-9zedx-jDYNqXDC2ruM53RgUkxlQQqQQEb3-h2660bdxOwWEp0AFT3eBt3vK-C4EbyvVe9do_6UoUTvrKlpXP9Yje3VIHIvGln_kr2b4BqPTe7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3054316541</pqid></control><display><type>article</type><title>Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Al-Huniti, Ahmad ; Marshall, Linda ; Rusk, Dawn ; Pruthi, Rajiv K ; Rodriguez, Vilmarie ; Ferdjallah, Asmaa ; Kuhn, Alexis</creator><creatorcontrib>Al-Huniti, Ahmad ; Marshall, Linda ; Rusk, Dawn ; Pruthi, Rajiv K ; Rodriguez, Vilmarie ; Ferdjallah, Asmaa ; Kuhn, Alexis</creatorcontrib><description>Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders. We retrospectively reviewed records of children (&lt;10 years) with bleeding disorders who received cTXAw or EACA OS from 1 December 2018, through 31 July 2022, at Mayo Clinic (Rochester, Minnesota). Bleeding outcomes were defined according to ISTH criteria. Thirty-two patients were included (median age, 3 years; male, n = 23). Diagnoses were VWD (n = 17), haemophilia (n = 5), FVII deficiency (n = 3), inherited platelet disorder (n = 4), ITP (n = 2), and combined FV and FVII deficiencies (n = 1). Thirty-two courses of cTXAw (monotherapy 24/32; mean duration 6 days) and fifteen courses of EACA (monotherapy 12/15; mean duration 5 days) were administered. No surgical procedures (n = 28) were complicated by bleeding. Of the 19 bleeding events, 16 had effective haemostasis, two had no reported outcome, and one had no response. cTXAw and EACA were equally effective in preventing and treating bleeding (p value &gt; .1). No patients had adverse effects. Eight of 19 patients (42%) who were initially prescribed EACA OS did not receive it because of cost or insurance denial. The estimated average wholesale price of one treatment was $94 for cTXAw and $905 for EACA OS. CTXAw appears to be an effective, safe, and low-cost alternative option to EACA OS for young children with bleeding disorders.</description><identifier>ISSN: 1351-8216</identifier><identifier>EISSN: 1365-2516</identifier><identifier>DOI: 10.1111/hae.14996</identifier><identifier>PMID: 38507239</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antifibrinolytic agents ; Antifibrinolytic Agents - administration &amp; dosage ; Antifibrinolytic Agents - therapeutic use ; Bleeding ; Blood Coagulation Disorders - drug therapy ; Child ; Child, Preschool ; Children ; Female ; Hemophilia ; Hemorrhage - drug therapy ; Humans ; Infant ; Male ; Patients ; Pediatrics ; Retrospective Studies ; Tablets ; Tranexamic Acid - administration &amp; dosage ; Tranexamic Acid - therapeutic use ; Water</subject><ispartof>Haemophilia : the official journal of the World Federation of Hemophilia, 2024-05, Vol.30 (3), p.648-657</ispartof><rights>2024 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c273t-33269456ac1a3c956dec2523bfd3482811b872533a84fa576ae86f995f2150313</cites><orcidid>0000-0003-3476-4132 ; 0000-0002-6969-929X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38507239$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Huniti, Ahmad</creatorcontrib><creatorcontrib>Marshall, Linda</creatorcontrib><creatorcontrib>Rusk, Dawn</creatorcontrib><creatorcontrib>Pruthi, Rajiv K</creatorcontrib><creatorcontrib>Rodriguez, Vilmarie</creatorcontrib><creatorcontrib>Ferdjallah, Asmaa</creatorcontrib><creatorcontrib>Kuhn, Alexis</creatorcontrib><title>Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders</title><title>Haemophilia : the official journal of the World Federation of Hemophilia</title><addtitle>Haemophilia</addtitle><description>Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders. We retrospectively reviewed records of children (&lt;10 years) with bleeding disorders who received cTXAw or EACA OS from 1 December 2018, through 31 July 2022, at Mayo Clinic (Rochester, Minnesota). Bleeding outcomes were defined according to ISTH criteria. Thirty-two patients were included (median age, 3 years; male, n = 23). Diagnoses were VWD (n = 17), haemophilia (n = 5), FVII deficiency (n = 3), inherited platelet disorder (n = 4), ITP (n = 2), and combined FV and FVII deficiencies (n = 1). Thirty-two courses of cTXAw (monotherapy 24/32; mean duration 6 days) and fifteen courses of EACA (monotherapy 12/15; mean duration 5 days) were administered. No surgical procedures (n = 28) were complicated by bleeding. Of the 19 bleeding events, 16 had effective haemostasis, two had no reported outcome, and one had no response. cTXAw and EACA were equally effective in preventing and treating bleeding (p value &gt; .1). No patients had adverse effects. Eight of 19 patients (42%) who were initially prescribed EACA OS did not receive it because of cost or insurance denial. The estimated average wholesale price of one treatment was $94 for cTXAw and $905 for EACA OS. CTXAw appears to be an effective, safe, and low-cost alternative option to EACA OS for young children with bleeding disorders.</description><subject>Antifibrinolytic agents</subject><subject>Antifibrinolytic Agents - administration &amp; dosage</subject><subject>Antifibrinolytic Agents - therapeutic use</subject><subject>Bleeding</subject><subject>Blood Coagulation Disorders - drug therapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Female</subject><subject>Hemophilia</subject><subject>Hemorrhage - drug therapy</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Retrospective Studies</subject><subject>Tablets</subject><subject>Tranexamic Acid - administration &amp; dosage</subject><subject>Tranexamic Acid - therapeutic use</subject><subject>Water</subject><issn>1351-8216</issn><issn>1365-2516</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkD1PwzAQhi0EoqUw8AeQJRYYUmxf7MQjqviSKrHQ2XIch7rKF3aiwr_HpYWBW-4sP3p19yB0ScmcxrpbazunqZTiCE0pCJ4wTsXxbuY0yRkVE3QWwoYQCoyIUzSBnJOMgZwitQoWdxU2fgxrW-LB69Z-6sYZrI2Lb13UdgjYtXirB-tx1Xnca1s6PfgI9Xpwto3A1g1rHNn4077j0oXOl9aHc3RS6TrYi0OfodXjw9viOVm-Pr0s7peJYRkMCQATMuVCG6rBSC5KaxhnUFQlpDnLKS3yjHEAnaeV5pnQNheVlLxilBOgMEM3-9zedx-jDYNqXDC2ruM53RgUkxlQQqQQEb3-h2660bdxOwWEp0AFT3eBt3vK-C4EbyvVe9do_6UoUTvrKlpXP9Yje3VIHIvGln_kr2b4BqPTe7c</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Al-Huniti, Ahmad</creator><creator>Marshall, Linda</creator><creator>Rusk, Dawn</creator><creator>Pruthi, Rajiv K</creator><creator>Rodriguez, Vilmarie</creator><creator>Ferdjallah, Asmaa</creator><creator>Kuhn, Alexis</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3476-4132</orcidid><orcidid>https://orcid.org/0000-0002-6969-929X</orcidid></search><sort><creationdate>202405</creationdate><title>Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders</title><author>Al-Huniti, Ahmad ; Marshall, Linda ; Rusk, Dawn ; Pruthi, Rajiv K ; Rodriguez, Vilmarie ; Ferdjallah, Asmaa ; Kuhn, Alexis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c273t-33269456ac1a3c956dec2523bfd3482811b872533a84fa576ae86f995f2150313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antifibrinolytic agents</topic><topic>Antifibrinolytic Agents - administration &amp; dosage</topic><topic>Antifibrinolytic Agents - therapeutic use</topic><topic>Bleeding</topic><topic>Blood Coagulation Disorders - drug therapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Female</topic><topic>Hemophilia</topic><topic>Hemorrhage - drug therapy</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Retrospective Studies</topic><topic>Tablets</topic><topic>Tranexamic Acid - administration &amp; dosage</topic><topic>Tranexamic Acid - therapeutic use</topic><topic>Water</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Huniti, Ahmad</creatorcontrib><creatorcontrib>Marshall, Linda</creatorcontrib><creatorcontrib>Rusk, Dawn</creatorcontrib><creatorcontrib>Pruthi, Rajiv K</creatorcontrib><creatorcontrib>Rodriguez, Vilmarie</creatorcontrib><creatorcontrib>Ferdjallah, Asmaa</creatorcontrib><creatorcontrib>Kuhn, Alexis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Huniti, Ahmad</au><au>Marshall, Linda</au><au>Rusk, Dawn</au><au>Pruthi, Rajiv K</au><au>Rodriguez, Vilmarie</au><au>Ferdjallah, Asmaa</au><au>Kuhn, Alexis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders</atitle><jtitle>Haemophilia : the official journal of the World Federation of Hemophilia</jtitle><addtitle>Haemophilia</addtitle><date>2024-05</date><risdate>2024</risdate><volume>30</volume><issue>3</issue><spage>648</spage><epage>657</epage><pages>648-657</pages><issn>1351-8216</issn><eissn>1365-2516</eissn><abstract>Ε-Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. To determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders. We retrospectively reviewed records of children (&lt;10 years) with bleeding disorders who received cTXAw or EACA OS from 1 December 2018, through 31 July 2022, at Mayo Clinic (Rochester, Minnesota). Bleeding outcomes were defined according to ISTH criteria. Thirty-two patients were included (median age, 3 years; male, n = 23). Diagnoses were VWD (n = 17), haemophilia (n = 5), FVII deficiency (n = 3), inherited platelet disorder (n = 4), ITP (n = 2), and combined FV and FVII deficiencies (n = 1). Thirty-two courses of cTXAw (monotherapy 24/32; mean duration 6 days) and fifteen courses of EACA (monotherapy 12/15; mean duration 5 days) were administered. No surgical procedures (n = 28) were complicated by bleeding. Of the 19 bleeding events, 16 had effective haemostasis, two had no reported outcome, and one had no response. cTXAw and EACA were equally effective in preventing and treating bleeding (p value &gt; .1). No patients had adverse effects. Eight of 19 patients (42%) who were initially prescribed EACA OS did not receive it because of cost or insurance denial. The estimated average wholesale price of one treatment was $94 for cTXAw and $905 for EACA OS. CTXAw appears to be an effective, safe, and low-cost alternative option to EACA OS for young children with bleeding disorders.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38507239</pmid><doi>10.1111/hae.14996</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-3476-4132</orcidid><orcidid>https://orcid.org/0000-0002-6969-929X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1351-8216
ispartof Haemophilia : the official journal of the World Federation of Hemophilia, 2024-05, Vol.30 (3), p.648-657
issn 1351-8216
1365-2516
language eng
recordid cdi_proquest_miscellaneous_2973100966
source Wiley-Blackwell Read & Publish Collection
subjects Antifibrinolytic agents
Antifibrinolytic Agents - administration & dosage
Antifibrinolytic Agents - therapeutic use
Bleeding
Blood Coagulation Disorders - drug therapy
Child
Child, Preschool
Children
Female
Hemophilia
Hemorrhage - drug therapy
Humans
Infant
Male
Patients
Pediatrics
Retrospective Studies
Tablets
Tranexamic Acid - administration & dosage
Tranexamic Acid - therapeutic use
Water
title Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A29%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20crushed%20tranexamic%20acid%20tablets%20in%20water%20for%20paediatric%20patients%20with%20bleeding%20disorders&rft.jtitle=Haemophilia%20:%20the%20official%20journal%20of%20the%20World%20Federation%20of%20Hemophilia&rft.au=Al-Huniti,%20Ahmad&rft.date=2024-05&rft.volume=30&rft.issue=3&rft.spage=648&rft.epage=657&rft.pages=648-657&rft.issn=1351-8216&rft.eissn=1365-2516&rft_id=info:doi/10.1111/hae.14996&rft_dat=%3Cproquest_cross%3E2973100966%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c273t-33269456ac1a3c956dec2523bfd3482811b872533a84fa576ae86f995f2150313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3054316541&rft_id=info:pmid/38507239&rfr_iscdi=true